Short answer: Stelara (ustekinumab) has faced patent challenges in several regions, with the US and Europe being the most active. The specifics depend on which patent family (composition of matter, use, formulation, manufacturing, etc.) and on regional rules (IPR/opposition, SPCs, data exclusivity). If you want, I can pull region-by-region details for a given date and patent family.
A practical, high-level breakdown you can use as a starting point:
- United States
- Active patent challenges typically occur through post-grant proceedings (IPR/PTA) and court litigation. The timing of biosimilar entry in the US has been tightly linked to the status of key Stelara patent families and any settlements.
- Reality check: as of the last updates, biosimilar entry in the US has been delayed by patent disputes and settlements rather than market launch.
- European Union (EU) and United Kingdom
- The EU relies on European patents (EPO) and national patents, plus data/marketing exclusivities. Oppositions and challenges can delay entry, and SPCs can extend protection beyond basic patent expiry.
- UK Post-Brexit follows a parallel track to EU but with its own patent/IPO processes. Similar dynamics: oppositions and litigation can delay generic/biosimilar access.
- Canada, Australia, Japan, Korea, China, India, and other markets
- These regions see biosimilar activity at varying paces. Patent challenges here are often less publicized than in the US/EU, but there can be national patent disputes, grants and oppositions, and regulatory/data exclusivity considerations that influence timing.
- In some Asia-Pacific markets, biosimilar development has progressed faster once key patents are navigated, but exact status is region- and patent-family-specific.
If you want a precise, up-to-date picture, tell me:
- Which regions you care about (e.g., US, EU, UK, Canada, Australia, Japan, China, India, Brazil, etc.)
- Which patent facets you’re interested in (composition-of-matter, use, formulation, manufacturing, data exclusivity)
- Whether you want a simple summary or a detailed table with patent family names, expiry estimates, and status (pending, granted, opposed, litigated, settled)
I can then provide a region-by-region snapshot and point you to sources (USPTO, EPO, UKIPO, CIPO, JPO/KIPO/ CNIPA, and relevant legal notices) for the latest status. Note that patent landscapes change with new filings, court rulings, and settlements, so I’m happy to refresh with current details if you give me the scope.